CHANTIX- varenicline tartrate tablet, film coated Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

chantix- varenicline tartrate tablet, film coated

avera mckennan hospital - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 0.5 mg - chantix is indicated for use as an aid to smoking cessation treatment. chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantix. risk summary available human data on the use of chantix in pregnant women are not sufficient to inform a drug associated risk. smoking during pregnancy is associated with maternal, fetal, and neonatal risks [see clinical considerations] . in animal studies, varenicline did not result in major malformations but caused decreased fetal weights in rabbits when dosed during organogenesis at exposures equivalent to 50 times the exposure at the maximum recommended human dose (mrhd). additionally, administration of varenicline to pregnant rats during organogenesis through lactation produced developmental toxicity in offspring at maternal exposures equivalent to 36 times human exposure at the mrhd [see data] . the estimated background risk of oral clefts is increased by approximately 30% in infants of women who smoke durin

ANTIZOL- fomepizole injection Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

antizol- fomepizole injection

paladin laboratories (usa) inc - fomepizole (unii: 83lcm6l2by) (fomepizole - unii:83lcm6l2by) - fomepizole 1 g in 1 ml - antizol®  is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see dosage and administration ). antizol®  should not be administered to patients with a documented serious hypersensitivity reaction to antizol®  or other pyrazoles.

antizol- fomepizole injection, solution Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

antizol- fomepizole injection, solution

fomepizole (unii: 83lcm6l2by) (fomepizole - unii:83lcm6l2by) - injection, solution - 1 g in 1 ml - antizol is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see dosage and administration ). antizol should not be administered to patients with a documented serious hypersensitivity reaction to antizol or other pyrazoles.

CHANTIX- varenicline tartrate kit Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

chantix- varenicline tartrate kit

a-s medication solutions - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 0.5 mg - chantix is indicated for use as an aid to smoking cessation treatment. chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantix. risk summary available data have not suggested an increased risk for major birth defects following exposure to varenicline in pregnancy, compared with women who smoke [see data]. smoking during pregnancy is associated with maternal, fetal, and neonatal risks (see clinical considerations) . in animal studies, varenicline did not result in major malformations but caused decreased fetal weights in rabbits when dosed during organogenesis at exposures equivalent to 50 times the exposure at the maximum recommended human dose (mrhd). additionally, administration of varenicline to pregnant rats during organogenesis through lactation produced developmental toxicity in offspring at maternal exposures equivalent to 36 times human exposure at the mrhd [see data] . the estimated background risk of oral clefts is increased by

CHANTIX- varenicline tartrate tablet, film coated Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

chantix- varenicline tartrate tablet, film coated

aphena pharma solutions - tennessee, llc - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 1 mg - chantix is indicated for use as an aid to smoking cessation treatment. chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantix. risk summary available human data on the use of chantix in pregnant women are not sufficient to inform a drug associated risk. smoking during pregnancy is associated with maternal, fetal, and neonatal risks [see clinical considerations] . in animal studies, varenicline did not result in major malformations but caused decreased fetal weights in rabbits when dosed during organogenesis at exposures equivalent to 50 times the exposure at the maximum recommended human dose (mrhd). additionally, administration of varenicline to pregnant rats during organogenesis through lactation produced developmental toxicity in offspring at maternal exposures equivalent to 36 times human exposure at the mrhd [see data] . the estimated background risk of oral clefts is increased by approximately 30% in infants of women who smoke durin

CHANTIX- varenicline tartrate tablet, film coated Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

chantix- varenicline tartrate tablet, film coated

proficient rx lp - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - chantix is indicated for use as an aid to smoking cessation treatment. chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantix. risk summary available data have not suggested an increased risk for major birth defects following exposure to varenicline in pregnancy, compared with women who smoke [see data]. smoking during pregnancy is associated with maternal, fetal, and neonatal risks (see clinical considerations) . in animal studies, varenicline did not result in major malformations but caused decreased fetal weights in rabbits when dosed during organogenesis at exposures equivalent to 50 times the exposure at the maximum recommended human dose (mrhd). additionally, administration of varenicline to pregnant rats during organogenesis through lactation produced developmental toxicity in offspring at maternal exposures equivalent to 36 times human exposure at the mrhd [see data] . the estimated background risk of oral clefts is increased by

OZMEP omeprazole 20 mg enteric-coated tablet blister Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

ozmep omeprazole 20 mg enteric-coated tablet blister

medis pharma pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: purified talc; hypromellose; iron oxide red; carnauba wax; sodium stearylfumarate; iron oxide yellow; titanium dioxide; sodium stearate; sodium lauryl sulfate; hypromellose acetate succinate; sodium starch glycollate; propylene glycol; lactose monohydrate; triethyl citrate; monoethanolamine - gastroesophageal reflux disease (gord). symptomatic gord: the relief of heartburn and other symptoms associated with gord. . erosive oesophagitis: the treatment and prevention of relapse. . peptic ulcers: the treatment of duodenal and gastric ulcer. . combination therapy for the treatment of peptic ulcer disease associated with h. pylori infection. . the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. . the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. . long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be h. pylori negative, or in whom eradication is inappropriate, e.g. the elderly or ineffective. . zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome

Amizide tablet Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

amizide tablet

alphapharm pty ltd - hydrochlorothiazide, quantity: 50 mg; amiloride hydrochloride dihydrate, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; lactose monohydrate; magnesium stearate; povidone; wheat starch - amizide is indicated in the treatment of patients with: oedema of cardiac origin; hepatic cirrhosis with ascites; hypertension in whom potassium depletion might be anticipated. amizide, with its combination of amiloride hydrochloride and hydrochlorothiazide, minimizes the possibility of the development of excessive potassium loss in patients during vigorous diuresis for prolonged periods. amizide, with it's built in potassium sparing agent, is especially indicated in those conditions where the positive effect on potassium balance is particularly important. hypertension. amizide may be used alone or as an adjunct to other anti-hypertensive drugs. since it enhances the action of these agents, the dosage of these antihypertensive drugs may need to be reduced to avoid the risk of an excessive drop in blood pressure.

Salazopyrin sulfasalazine 500mg tablet Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

salazopyrin sulfasalazine 500mg tablet

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; maize starch - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: salazopyrin en-tabs are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Salazopyrin EN Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

salazopyrin en

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; macrogol 20000; carnauba wax; magnesium stearate; povidone; cellacefate; maize starch; propylene glycol; colloidal anhydrous silica; glyceryl monostearate; purified talc - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: salazopyrin en-tabs are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).